Hematologic Oncology

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Epcoritamab plus rituximab and lenalidomide met the dual primary end points of the EPCORE FL-1 in relapsed/refractory follicular lymphoma.

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.